• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Silva ID Cancer epidemiology


    7. Silva ID. Cancer epidemiology: principles and methods. Lyon,
    France: International Agency for Research on Cancer; 1999. 
    8. Saracci R, Wild C. International agency for research on cancer: the
    9. World Health Organization. National cancer control programmes. Policies and managerial guidelines. 2nd ed. Geneva: WHO press; 2002.
    10. Bray F. Planning and developing population-based cancer registration in low- and middle-income settings. Lyon: IARC (International Agency for Research on Cancer); 2014.
    11. International cancer Y 27632 welcomes global Initiative for cancer registry development in low- and middle-income countries. Retrieved iarcnews/pdf/GICR.pdf; 2011. Accessed July 12, 2016.
    12. Africa Population Statistics in Maps and Charts. Accessed¼7946. Accessed August 28, 2017.
    14. Islam SM, Purnat TD, Phuong NT, Mwingira U, Schacht K, Fro¨schl G. Non-Communicable Diseases (NCDs) in developing countries: a symposium report. Global Health. 2014;10:1e7.
    15. WHO Office of Nigeria, W. Atlas of African Health Statistics 2016 : Health situation analysis of the African Region. Retrieved from files/publications/5266/Atlas-2016-en.pdf.
    16. Nwogu CE, Mahoney M, Okoye I, et al. Role of private enterprise in cancer control in low to middle income countries. J Cancer Epidemiol. 2016;2016:1e5.
    18. African Cancer Registry Network. Nigerian National System of Cancer Registries. Retrieved members/108-nscr. Accessed July 18, 2016.
    20. Odedina FT, Asante-Shongwe K, Kandusi EJ, et al. The African cancer advocacy consortium: shaping the path for advocacy in Africa. Infect Agents Cancer. 2013;8(Suppl 1):s8.
    21. Jedy-Agba EE, Oga EA, Odutola M, et al. Developing national cancer registration in developing countries e case study of the Nigerian national system of cancer registries. Front Public Health. 2015;3:186.
    Contents lists available at ScienceDirect
    Medical Hypotheses
    journal homepage:
    Cancer related fatigue and cancer cachexia are the consequence of endocrine T failure caused by persistent stress
    Shaoqing Lai
    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Cancers related fatigue
    Cancer cachexia
    Endocrine hypofunction
    This study researches the cause of tumor, cancer related fatigue (CRF) and cancer cachexia (CC), and the re-lationship among tumor and CRF and CC.
    Carcinogenesis is consequence of failure of tissue development. Tumor originates from tissue regeneration. The tumor cell is normal incomplete differentiated cell that stop in different phases of differentiation. Tumor promoter stimulates stem cell to proliferate. Carcinogen obstructs stem cell to differentiate. With tumor pro-moter and carcinogen, the tissue stem cells proliferate but cannot differentiate into mature cell, and form tumors. The disorder of biological signals cell proliferation and differentiation facilitates tumor development.
    CRF and CC are consequence of endocrine hypofunction and failure caused by persistent stress. Nature factors and psychological factors stimulate organic stress. The significant change of stress is the activation of endocrine system. The persistent stress exhausts the capacity of endocrine glands or hormone receptors of target cells, and leads to endocrine hypofunction even failure. CRF and CC are clinical manifestation of endocrine hypofunction and failure.
    Cancer is a local lesion, also is a systemic disease. As a local lesion, carcinogen obstructed stem cell to differentiate, developmental failure of local tissue forms tumor. As a systemic disease, cancer is related to natural physical, chemical, and biological factors, as well as negative spiritual factors. The material and spiritual factors induce persistent stress which eventually leads to endocrine hypofunction even failure and unbalance of homeostasis. The disorder of biological signals of cell proliferation and differentiation facilitates tumor devel-opment.
    CRF and CC, as clinical manifestation of endocrine hypofunction and failure, have nothing to do with tumor size and type, but facilitate tumor development. CRF and CC are through all the course of systemic cancerous disease, and commonly precede tumorigenesis. Many patients have been found tumors because of symptoms of CRF and CC. Even if no tumor be found at that time, various tumors would be found in Y 27632 the follow-up.